Compound I [28] (Figure 1) and compound II [29] (Figure 1) revealed antibreast cancer effects related to EGFR (IC50= 0.06 μM) and HER2 inhibition (IC50= 0.18 μM), respectively. The gene discussed is ERBB2; the disease is cancer.